Suchergebnisse

In the last three decades, the People's Republic of China (PRC) has managed to replace its welfare-based urban housing system with a market-based housing provision scheme. With such significant housing policy changes, the PRC has successfully expanded urban home ownership and impressively increased per capita housing consumption. The housing market has become one of the major pillar industries in the country's economic boom. However, affordable housing development has been greatly lagging behind the ever-increasing housing needs of a large lower-income population in the country, while housing price bubbles cast a shadow on sustainable economic development in the PRC. The main reasons for such challenges include the inefficiency of financial tools to regulate the housing market; and the discrete interests among the central government, local governments, and real estate developers. Within the context of the ongoing global financial crisis, it is even more critical to balance the PRC's housing development, both to address the people's housing needs, and to maintain sustainable growth.

Abstract
Knowledge and trust are generally viewed as key drivers of favorable attitudes toward technology, but it remains uncertain whether and how different types of knowledge and trust interact with each other in predicting public acceptance. To address this gap, the present study hypothesized that knowledge and trust would exert both main and interaction effects on public opinion. Data from a national survey of public attitudes toward genetic modification (GM) in China were used to test an interactive model of attitudes. We have found that factual knowledge of and perceived familiarity with GM and trust in university scientists interacted as complements, with knowledge impacting positive attitudes more strongly for people who had high levels of trust; while we found no such interaction for knowledge/familiarity and trust in industry scientists and governmental officials. The implications of these findings for future research and policymaking in the domain of science and risk communication are discussed.

The dynamics of international economic competition have prompted governments to re-examine accustomed policies, and search for alternative strategies, in order to re-position their economies for the future. This paper takes a look at Singapore's search for a competitive positioning in the global marketplace, and focuses on the city-state's much-publicized, and controversial, flagship project in China, viz, the Suzhou Industrial Park (SIP). This strategic initiative is premised on the perceptions that Singapore's positive reputation with multinational corporations, and 'guanxi' (or connections) with regional governments, will give the regional sites a strategic advantage in the competition for foreign investments. Earlier studies have established that the privileges secured for the investment enclaves are vulnerable to changes in the socio-political milieu, and that Singapore's reputation for efficiency, is at risk from the administrative complexities in emerging economies. This paper, however, contends that with the 'realignment of interests' in 2001, the outlook of the SIP project is promising.

Lu-Hua Gao, Qing-He Nie, Xi-Tai Zhao Center of Infectious Diseases, Second Affiliated Hospital, Air-Force Military Medical University, Xi'an 710038, People's Republic of ChinaCorrespondence: Qing-He NieCenter of Infectious Diseases, Second Affiliated Hospital, Air-Force Military Medical University, 569 Xinsi Road, Baqiao District, Xi'an 710038, People's Republic of ChinaEmail nhqxan2020@163.comAbstract: Hepatitis C is a major health problem worldwide, frequently resulting in cirrhosis and increasing the risk of hepatocellular carcinoma significantly. In recent years, the advent of direct-acting antivirals (DAAs) has dramatically improved the therapeutic outcomes in hepatitis C patients. In the last two years, several new DAA combinations have been approved for the treatment of the hepatitis C virus (HCV) infection, including elbasvir/grazoprevir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir, and glecaprevir/pibrentasvir. The newly approved DAA regimens may be prescribed with other drugs simultaneously, increasing the potential of pharmacokinetic interactions. Therefore, the knowledge and management of drug–drug interactions (DDIs) with DAAs should be considered a key issue in HCV therapy. This review summarizes researches of DDIs focusing on newly approved DAAs (elbasvir, grazoprevir, velpatasvir, voxilaprevir, glecaprevir, pibrentasvir) for patients undergoing HCV treatment to provide clinical consideration for comedication. With respect to DDIs, newly approved DAA regimens, including elbasvir/grazoprevir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir, and glecaprevir/pibrentasvir, are safely applicable.Keywords: drug–drug interaction, direct-acting antiviral, chronic hepatitis C, pharmacokinetic, comedication